Trending Articles

article thumbnail

Collaborative Drug Discovery and deepmirror Announce Collaboration for Humanitarian and Commercial Drug Discovery

Collaborative Drug

BURLINGAME, Calif. — July 8, 2025. Collaborative Drug Discovery (CDD) , the leading provider of data management solutions for the pharmaceutical and biotechnology industries, and deepmirror , the AI drug design platform that empowers chemists to focus on more promising drug molecules, today announced a strategic partnership integrating deepmirror with CDD Vault to enhance drug discovery.

130
130
article thumbnail

Discovery of the Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19

Covalent Modifiers

Yuto Unoh, Keiichiro Hirai, Shota Uehara, Sho Kawashima, Haruaki Nobori, Jun Satom, Hiromitsu Shibayama, Akihiro Hori, Kenji Nakahara, Kana Kurahashi, Masayuki Takamatsu, Shiho Yamamoto, Qianhui Zhang, Miki Tanimura, Reiko Dodo, Yuki Maruyama, Hirofumi Sawa, Ryosuke Watari, Tetsuya Miyano, Teruhisa Kato, Takafumi Sato,Yuki Tachibana J. Med. Chem. 2025 [link] The coronavirus disease 2019 (COVID-19) pandemic crisis has been mitigated by worldwide efforts to develop vaccines and therapeutic drugs.

130
130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Deafness reversed: Single injection brings hearing back within weeks

Science Daily: Pharmacology News

A cutting-edge gene therapy has significantly restored hearing in children and adults with congenital deafness, showing dramatic results just one month after a single injection. Researchers used a virus to deliver a healthy copy of the OTOF gene into the inner ear, improving auditory function across all ten participants in the study. The therapy worked best in young children but still benefited adults, with one 7-year-old girl regaining almost full hearing.

Virus 277
article thumbnail

Regeneron bispecific approved for myeloma; Concentra to buy IGM

BioPharma Drive: Drug Pricing

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

248
248
article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk

Drugs.com

WEDNESDAY, July 2, 2025 -- The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain formulations of amphetamine and methylphenidate, to warn.

FDA 284
article thumbnail

Ultrafast 12-minute MRI maps brain chemistry to spot disease before symptoms

Science Daily: Pharmacology News

Illinois engineers fused ultrafast imaging with smart algorithms to peek at living brain chemistry, turning routine MRIs into metabolic microscopes. The system distinguishes healthy regions, grades tumors, and forecasts MS flare-ups long before structural MRI can. Precision-medicine neurology just moved closer to reality.

Disease 227

More Trending

article thumbnail

Medicaid, Medicare Don't Adequately Cover Addiction Treatment, Study Says

Drugs.com

TUESDAY, July 1, 2025 — Opioid addicts covered by Medicare and Medicaid are less likely to receive the mental health and substance use treatment that they need, a new study says. Addicts with public insurance receive more than twice as many.

Treatment 269
article thumbnail

Computationally Guided Structural Modification of Centaureidin: A Novel Approach for Enhancing Antioxidant and Antitumor Activities for Drug Development

Chemical Biology and Drug Design

Computationally guided modifications of centaureidin led to the development of CA4, demonstrating enhanced antioxidant and antitumor activities. Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy. ABSTRACT The development of novel therapeutic drugs with enhanced efficacy has gained significant attention in recent years.

article thumbnail

The AI model that is changing clinical trial design

Drug Target Review

Clinical trials are expensive, slow and often limited by outdated design constraints. Placebo arms, in particular, create ethical and logistical hurdles, especially in areas like rare disease and oncology. Digital twins offer a way forward. They offer patient-specific outcome predictions, generated using machine learning models trained on real historical clinical data.

article thumbnail

Is that really ADHD? Why flawed trials may be misleading millions

Science Daily: Pharmacology News

Researchers reviewing nearly 300 top-tier ADHD drug trials found that half skipped the rigorous, expert-led evaluations needed to rule out other conditions like depression or schizophrenia. With diagnoses often made by unqualified staff—or even by computer—many participants may not have actually had ADHD, casting doubt on study outcomes that shape treatment guidelines.

Trials 207
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Atai and Beckley, set to merge, reveal study success for psychedelic drug

BioPharma Drive: Drug Pricing

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray into pivotal testing.

Drugs 147
article thumbnail

CDC Now Recommends RSV Vaccine for Some Adults 50+

Drugs.com

MONDAY, July 7, 2025 — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update from the U.S. Centers for Disease Control and Prevention (CDC). This marks a change from the.

Vaccine 257
article thumbnail

In Vitro and In Silico Evaluation of Isatin‐Derived Spirooxindoles as Antituberculosis Drug Candidates

Chemical Biology and Drug Design

Two compounds, A16 and A17, were active against multidrug-resistant Mycobacterium tuberculosis isolates (PT-12 and PT-20), overcoming key resistance mutations in katG and rpoB, while cytotoxicity assays confirmed that they are non-toxic. A17 exhibited the highest antituberculosis activity, with molecular docking suggesting enoyl-[acyl-carrier-protein] reductase as a potential biological target.

article thumbnail

Future-proofing drug development with GenAI

Drug Target Review

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. However, R&D stakeholders are learning that GenAI underpinned by domain expertise also enables deep dives into the broader long-term potential of their investigational asset(s) as early as the preclinical phase.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

The fatal mutation that lets cancer outsmart the human immune system

Science Daily: Pharmacology News

Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers than our primate cousins. The change affects a protein used by immune cells to kill tumors—except in humans, it’s vulnerable to being shut down by an enzyme that tumors release. This flaw may be one reason treatments like CAR-T don’t work as well on solid tumors.

Treatment 227
article thumbnail

Apogee touts positive data for atopic dermatitis drug

BioPharma Drive: Drug Pricing

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less frequent dosing.

147
147
article thumbnail

IBS Rates Nearly Doubled During the Pandemic

Drugs.com

MONDAY, July 1, 2025 — The COVID-19 pandemic took a toll on Americans’ guts, researchers report. Gut disorders like irritable bowel syndrome (IBS) increased significantly during the COVID-19 pandemic, a new study says. Rates of IBS.

Research 245
article thumbnail

Fast Determination of Protein Binding Constants and Sites to Active Flavonoids and Phenolic Acids by Affinity Capillary Electrophoresis and Fluorescence Spectroscopy

Chemical Biology and Drug Design

Determination of binding ability of flavonoids/phenolic acids to HSA by affinity capillary electrophoresis and fluorescence spectroscopy. ABSTRACT The interaction of small molecule drugs with human serum albumin (HSA) after entering the human blood circulation system profoundly affects their distribution and absorption in the body, and further influences the activity.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

PALAZESTRANT

New Drug Approvals

PALAZESTRANT CAS 2092925-89-6 OP-1250, VU35KM56Q4 449.6 g/mol, C 28 H 36 FN 3 O (1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-{4-[(1-propylazetidin-3- yl)oxy]phenyl}-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Palazestrant (OP-1250) is an investigationa

article thumbnail

Banned in Europe, sprayed in America: The fungicide threatening our pollinators

Science Daily: Pharmacology News

Macquarie University researchers reveal that chlorothalonil, still commonly sprayed on American and Australian produce, cripples insect fertility by more than a third at residue levels typically found on food. The unexpectedly sharp drop in fruit-fly egg production suggests cascading damage to pollinator populations vital for crops and ecosystems. Although the fungicide is outlawed in the EU, Australian growers often apply it preventively, underscoring regulatory blind spots.

article thumbnail

After delay, Kalvista wins FDA OK for drug to treat rare swelling disorder

BioPharma Drive: Drug Pricing

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an on-time approval.

162
162
article thumbnail

Clash Of Drugs Impedes Lung Cancer Treatment, Lowers Survival

Drugs.com

TUESDAY, July 7, 2025 — Two drugs used in lung cancer treatment appear to be tripping over each other, reducing patients’ chances for a cure, a new study says.Corticosteroids are commonly prescribed to alleviate cancer-related symptoms in patients w.

130
130
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

How dual-targeting ADCs aim to tackle resistance

Drug Target Review

Dr Eleni Lagkadinou is on a mission to fast-track the future of cancer care. As Vice President of Oncology Early Development (OED) at AbbVie , she leads the charge on translating bold scientific ideas into real-world impact – and she’s doing it with a focus on some of the most tenacious cancers out there. With a background spanning drug development, clinical strategy and translational research, Eleni brings more than two decades of experience to the role.

52
article thumbnail

Key assays and analytical techniques for the development of antibody drug conjugates

Crown Bioscience

Highly targeted antibody-drug conjugates (ADCs) combine an antibody with a cytotoxic payload, covalently attached via a chemical linker. These “ biological missiles ” represent an exciting new advance in anti-cancer therapies and are one of the fastest-growing segments in oncology drug development. Due to their complex make-up and multiple components, analysis of their chemistry and functionality is challenging, requiring advanced assays and techniques for effective study and characterization.

Drugs 52
article thumbnail

Scientists reverse Parkinson’s symptoms in mice — Could humans be next?

Science Daily: Pharmacology News

Scientists at the University of Sydney have uncovered a malfunctioning version of the SOD1 protein that clumps inside brain cells and fuels Parkinson’s disease. In mouse models, restoring the protein’s function with a targeted copper supplement dramatically rescued movement, hinting at a future therapy that could slow or halt the disease in people.

Therapies 150
article thumbnail

Study results boost Cogent’s case for rare disease drug

BioPharma Drive: Drug Pricing

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a competitor to Blueprint Medicines’ Ayvakit.

147
147
article thumbnail

Could Dairy Be Causing Your Bad Dreams?

Drugs.com

WEDNESDAY, July 2, 2025 — Having bad dreams after eating ice cream or cheese? Your stomach may be trying to tell you something. New research shows that people with worse symptoms of lactose intolerance tended to report more frequent.

Research 237
article thumbnail

Time for change: non-human primates in drug research

Drug Target Review

Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drug development due to their close genetic, anatomical and physiological resemblance to humans. Their unique suitability has made them valuable for evaluating pharmacokinetics, toxicology and safety in drug candidates before human clinical trials.

article thumbnail

Assembling data sets for training ML bioactivity models

Molecular Design

Here’s a photo from one of my exercise walks in Paramin and you can see the Caribbean Sea in the distance. This is perhaps my favourite view on the walk because it means that I’ve just got to the top of a particularly brutal hill (cars sometimes struggle to get to the top and on one occasion I watched a car fail miserably in four attempts) although you can’t always see the sea as clearly as in this photo.

article thumbnail

Cough medicine turned brain protector? Ambroxol may slow Parkinson’s dementia

Science Daily: Pharmacology News

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over 12 months, whereas placebo patients worsened. Those with high-risk genes even saw cognitive gains, hinting at real disease-modifying power.

Disease 133
article thumbnail

Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline

BioPharma Drive: Drug Pricing

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.

article thumbnail

Measles Outbreak in Kentucky Confirmed

Drugs.com

THURSDAY, July 3, 2025 -- There has been nationwide total of 1,267 confirmed cases of measles this year, with Kentucky being the latest state to announce an outbreak, the U.S. Centers for Disease Control and Prevention reported Wednesday.There are.

Disease 236
article thumbnail

Analyzing Oxygen Atom Distribution in FDA‐Approved Drugs to Enhance Drug Discovery Strategies

Chemical Biology and Drug Design

Analysis of prevalence of ring, nonring, sp 3 -, and sp 2 -hybridized oxygen in approved drugs. For the first time, analysis of distribution of different types of oxygen from center of mass of a molecule. ABSTRACT Despite advancements in molecular design rules and understanding biochemical processes, the field of drug design and discovery seeks to minimize the number and duration of synthesis-testing cycles to convert lead compounds into drug candidates.